Citation:Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007

Citation

Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007 Sep;2(9):845-53 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17805063.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007 2	Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007 3	Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007 4	Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA 2007 5	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?
2. Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?
3. What is the optimal systemic therapy for stage IV inoperable NSCLC?
4. What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?
5. Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?